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Abstract: In the era of increasing antibiotic resistance, the use of alternative antimicrobials such as silver 
has become more widespread. Superior antimicrobial activity has been provided through creation of 
silver nanoparticles or nanosilver (NAg) that impart cytotoxic actions distinct from bulk silver. In the 
wake of the recent discoveries of bacterial resistance to NAg and its rising incorporation in medical and 
consumer goods such as wound dressings and dietary supplements, we argue an urgent need to monitor 
the prevalence and spread of NAg microbial resistance. This Perspective describes how the use of NAg in 
commercially available products facilitates prolonged microorganism exposure to bioavailable silver, 
which underpins the development of resistance. Furthermore, we advocate for a judicial approach 
towards NAg use in order to preserve its efficacy and avoid environmental disruption.       
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Silver has long been used as an antimicrobial but its effectiveness is now under threat  
Humans, since their first existence, have had to co-exist with microorganisms and adapt to their 
dominating presence1. Microorganisms reside in our bodies and we are increasingly aware of the extent to 
which communities of microorganisms shape our physical and mental health and of the value in keeping 
these communities in balance1. To manage those among the microorganisms that are or become 
pathogenic, we use antimicrobials either prophylactically, to prevent infection, or as treatment for 
established infection. Antimicrobials include more than antibiotics; before and since the discovery of 
antibiotics other antimicrobials have been used, including disinfectants, and notably, silver. Silver has 
broad-spectrum antimicrobial activity2 and yet seemingly low toxicity for humans3. As resistance to 
antibiotics rises exponentially and resistance to new-generation biocides such as triclosan appears4,5, the 
ability to rely on silver and other less conventional antimicrobial treatments assumes even greater 
importance and this has led to growing momentum in the design, engineering and applications of 
nanosilver (NAg)6-8. The appeal of NAg is that its distinct physical, chemical and biological properties 
deriving from its smaller size (metallic or oxide silver particulates with 1-100 nm dimensions of the 
particles) afford its greater efficacy as an antimicrobial at lower concentrations, relative to larger micron-
sized bulk silver.   
The reliability of silver as an antimicrobial is, however, under threat. In 2014, the European 
Commission’s Scientific Committee on Emerging and Newly Identified Health Risks (SCENIHR)9, 
recognised a ‘serious knowledge gap’ concerning the use of silver nanoparticles and the potential 
consequent development of resistance mechanisms to them. This Perspective analyses this potential 
consequence and argues that a real threat exists that resistance to antimicrobial NAg will develop and 
propagate throughout communities of microorganisms, including those that reside in our bodies. Fuelling 
this threat is the rapid, widespread, and indiscriminate expansion of NAg application. NAg is now used as 
a core or co-antimicrobial ingredient in consumer products across numerous application categories, with 
major usage in health and fitness (personal care, medical care, as dietary supplements), in clothing and 
other textiles, as well as in home and garden (filters, household appliances and cleaning) and even baby 
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products10,11. Here, we examine the NAg applications in medical care and dietary supplements for their 
potential to facilitate prolonged microorganism exposure to bioavailable silver, a key factor in 
development of resistance in microbial communities. These NAg applications involve direct human 
contact, facilitating the potential release, absorption, distribution and in turn, accumulation of bioavailable 
silver in microorganism-inhabited organs and tissues. 
The terminology of bioavailable silver from nanosilver 
The emphasis in this Perspective will be on ‘bioavailable silver’ – a term we use in relation to NAg 
that refers to both Ag particulates and soluble Ag that leach from such particulates; the emphasis here is 
on bioavailable silver rather than on whether the product on the shelf contains silver or NAg (Box 1 and 
Figure 1). This emphasis is because not all forms of silver exert cytotoxicity against microorganisms. 
Silver can be present in a product in one form (metallic silver (Ag(0)) particulates, silver oxide 
particulates, or cationic silver in various compounds) but can transform through aggregation, 
agglomeration, dissolution and chemical speciation into alternative forms when the product is in use12. 
That is, when the silver makes contact with a new environment, such as those occurring when wound 
dressings are applied and contact is made with the body fluids. Cytotoxic action against microorganisms 
depends on the bioavailability of the silver, and it is increasingly realised that silver nanoparticles, their 
bulk silver (>100 nm) counterparts and cationic silver have distinct cytotoxic actions on 
microorganisms13-16.  NAg exhibits superior size- and shape- dependent antimicrobial activity through the 
action of undissolved Ag particulates, in addition to that from the ‘nano-sized’ enhanced leaching of 
soluble silver13,14,17-19. Thus, our emphasis is guided by the fact that what is important for the 
development of resistance to silver is the prolonged exposure of a microorganism to forms of silver that 
are able to exert biological action on the cell, rather than the form of silver in the product at the point of 
sale. Attention is drawn particularly to NAg because of its exponential applications, for which 
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Microorganisms can develop resistance to nanosilver 
Before the dramatic increase in application of silver nanoparticles as an antimicrobial, ionic silver has 
had a long history of use as a disinfectant. Many reports frequently use the term ‘silver’ when referring to 
silver ions. Decades-old discoveries provide evidence on the potential of microorganisms to develop 
resistance to chemical species of silver that are cytotoxic, so that the microorganisms continue to grow 
even in the presence of silver. One of the earliest reports of antimicrobial resistance to silver ions was by 
Jelenko et al.in 1969. The study isolated resistant Escherichia coli from a clinical case of prolonged silver 
nitrate-treated burns (detected at day 47, following treatment with 0.5 % silver nitrate at day 1 and day 36 
post-burn)23. This was followed by the discovery of a silver-resistant Salmonella typhimurium strain in 
the 1970s, also isolated from clinical cases of silver nitrate-treated burns (detected as early as day 8, 
following treatment with 0.5% silver nitrate)24. The isolated strain was later characterised as having nine 
resistance determinants, known as the sil genes25. Examples of bacteria adapting to conditions of long 
exposure to silver are also found outside the clinic, in specific environmental settings ‘where toxicity 
might select for resistance’ (a quote from A. Gupta and S. Silver, 1998), including the soil of a silver 
mine and photographic laboratory effluent6,26. 
Given the difference in cytotoxic action against microorganisms by different silver chemical species, it 
may not necessarily follow from the earlier studies that microorganisms exposed to silver nanoparticles 
will adapt and develop resistance traits to the nanoparticle exposure. It is thus an important question to 
ask: can microorganisms develop resistance to NAg?    
The answer is yes, they can. In 2013, we reported the natural ability of the ubiquitously occurring 
Bacillus sp. bacteria genus to adapt to NAg in the forms of both high tolerance to NAg and enhanced 
proliferation27. The ability of Bacillus sp. to grow when exposed to NAg levels higher than the microbial 
toxicity threshold is a result of prolonged prior exposure to NAg. Although the mechanisms by which 
microorganisms develop resistance effects to NAg are yet to be understood, they may involve defence to 
oxidative damage invoked by exposure to bioavailable silver27. Notably, lethal levels of NAg-stimulated 
cellular oxidative stress were not required for resistance to develop in Bacillus sp.; the resistance effects 
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also developed upon prolonged exposure to benign levels of NAg-stimulated cellular oxidative stress. The 
observed adaption was maintained in the population so that the enhanced proliferation continued even in 
the absence of NAg exposure. The enhanced proliferation of the Bacillus sp. enabled them to dominate 
the model microbiota that was the subject of the study (detection of resistant Bacillus sp. as early as day 3 
using 3 mg Ag/L)27. Bacillus sp. were not the target of the application of NAg – E. coli was, but were 
rather an environmentally-occurring airborne microorganism introduced at low-levels to contribute to a 
test microbiota. Similarly, another resistance study to NAg by Khan et al. detected resistant Bacillus sp. 
from sewage, this time in only 24 h using the extremely high 100 mg Ag/L28. In 2015, Graves et al. 
observed NAg tolerance in E. coli of clinical origin, again manifesting upon prolonged exposure 
(detection between 23 to 29 days of treatment with 50 to 125 µg/L NAg)29. 
Published studies describing resistance to various forms of silver raise the cornerstone question for this 
Perspective: could the increased use of NAg in a wide range of products facilitate prolonged 
microorganism exposure to bioavailable silver and therefore the development of resistance in real-world 
settings? And more importantly, how? To address these questions, we investigated more than 140 
commercially-available medical care and dietary supplement products with proven NAg contents or 
proven presence of Ag for the claimed NAg or Ag ingredients, with reference to published scholarly 
articles as well as manufacturer-funded in vitro and in vivo studies. In our analysis, we identified the 
following: (1) the potential release of Ag ions upon contact with body fluids, (2) the subsequent routes of 
absorption, distribution and accumulation of Ag along with its corresponding chemical transformation 
and finally, (3) the potential exposure of microflora at sites with prolonged accumulation of bioavailable 
Ag (see Supplementary Table S1, S2 and S3). Our investigation took into account the complexities of 
silver. Incorporation of non-nanoscale silver in the products, such as silver salts and micron-sized metallic 
silver, could in fact result in the formation and release of ‘secondary’ NAg particulates. Ionic silver is 
capable of undergoing chemical transformation to form nano-sized Ag particulates in biological 
environments12,30,31, while metallic silver even as large pieces, has been shown to release NAg 
particulates under humidity-dependent conditions32. In summary, our investigation found that applications 
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of NAg (or silver) in medical care or as dietary supplements could facilitate prolonged microorganism 
exposure to bioavailable silver in the human body and therefore, the potential for resistance development. 
Likely sites for exposure within the human body that we identified include wound bed, oral cavity, 
gastrointestinal and urinary tracts, all densely-populated microbial habitats with persistent presence of 
bioavailable silver (Figure 2), as described in more detail below. 
Increasing use of nanosilver products can facilitate prolonged microorganism exposure to 
bioavailable silver 
The commercialisation of silver-containing medical products has seen incorporation of many forms of 
silver ranging from bound cationic Ag(I), such as silver sulphadiazine and silver sulfate, to the more 
current and technologically advanced applications of nanocrystalline metallic and oxide silver (Table S1). 
For wound dressings, these various forms of silver are coated on or impregnated in alginates, polymer-
based mesh, fibres and foams as well as hydrogels, hydrofibres and hydrocolloids. Incorporation of silver 
in catheters involves coating of latex or silicone base materials with the silver in alloyed or hydrogel 
forms. The desired antimicrobial activity observed for these silver-containing products originates from 
their contact with relevant body fluids – wound exudates for wound dressings, bloodstream, urine or 
respiratory tract fluid for central venous, foley or tracheal catheters respectively, sustainably releasing Ag 
ions over a prolonged period33,34. Typically 3 to 7 days and for some products, up to 21 days of Ag ion 
release, have been observed or claimed for wound dressings, while longer release periods of 4 weeks or 
more are generally the case for catheters. An often overlooked, yet crucial, fact is that the bioavailability 
and therefore the cytotoxicity of the released Ag ions is affected by their further interactions with halide 
anions (Cl-, Br-, I-) as well as biomolecules and proteins as silver-precipitating and silver-complexing 
agents in the body fluids30,33,35. For example, the soluble Ag(I)-halide anionic complexes (such as AgCl2
-, 
AgCl3
2-) and organo Ag-peptide complexes can interact with bacteria and cause cytotoxicity30,36-38. If 
present in microbial habitats, the prolonged generation of these bioavailable silver species from the 
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To clearly demonstrate this, let us take a closer look at the fates, the series of chemical transformation 
and the potential of prolonged microorganism exposure to the bioavailable silver derived from wound 
dressings (see Table S1 for more details). Upon their release, Ag ions interact with the typically abundant 
presence of chloride and serum proteins in the wound environment39. Such interactions will potentially 
result in the formation of bioavailable Ag species – the soluble Ag(I)-chloride anionic complexes (e.g. 
AgCl2
-, AgCl3
2)33,36,37, organo Ag complexes33,38, with a maximum of 1 µg/mL silver expected to remain 
as free ions40. Note that there could also be presence of the biologically inert AgCl precipitate33,35,36 and 
in the case of NAg dressings, the likely presence of Ag particulates on wound beds will contribute to 
additional cytotoxic effects13,14 (also see Table S3 for forms of  silver species in wounds and their 
bioavailability). Localised exposure of wound microflora to such continual presence of bioavailable silver 
could facilitate resistance development, in particular with the repeated wound dressing applications on the 
infection-prone burns and chronic wounds. Apart from contamination by members of the gastrointestinal 
(gut), the oral cavity and the genitourinary microflora41, wounds are also a potential breeding ground for 
members of the surrounding skin microflora and even the exogenous air-borne microorganisms41,42, of 
which the latter include Bacillus sp.43,44. With a bacterial burden of at least 105 CFU (colony forming 
units) per gram tissue typically observed in infected wounds41,45, there have indeed been incidences of 
prevalence and  invasive infections of silver-resistant bacteria arising from the wound care applications of 
silver46-48. This is not contradictory to the in vitro observation of aggressive proliferation of resistant 
bacteria (exogenous Bacillus sp.) following prolonged exposure to NAg27. Further, bacteria containing sil 
genes with increased persistence to growth inhibition by silver have been detected in members of wound 
microflora49; although we do not rule out the possibility that such prevalence may be partly attributed to 
the phenomena of microorganism-to-microorganism transfer of resistance determinants, as later 
discussed. In 2016, a spontaneous resistance phenomenon was observed in the wound pathogen Proteus 
mirabilis following one-off exposure to NAg wound dressings, presenting a firmer evidence on the 
potential implications of NAg wound care applications50. 
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The fate of silver applied to the body through application of wound dressings is not limited to chemical 
transformations and accumulation in wounds. In cases of prolonged wound dressing application and/or 
treatment of large wounds, silver has been found to enter the bloodstream through systemic absorption 
(see Table S1)34. Here, the absorbed Ag species predominantly exist as organo species due to the high 
affinity of Ag ions for the thiol (-SH) groups of the amino acids cysteine and methionine present in serum 
albumins, metallothioneins and macroglobulins51-53 as well as in reduced glutathione (GSH), a small 
antioxidant peptide30,54. Ag ions also have strong affinities for the amino acids histidine, arginine and 
lysine55-57, which are also thought to be the preferential binding sites of silver in peptides, proteins and 
biomolecules12. Note that it remains unclear at this stage as to the exact routes of silver absorption into the 
bloodstream and the identities of the absorbable silver species, with several research inquiries leaning 
toward the systemic uptake of Ag ions30,34 and Ag complexes with mobile proteins34. Detection of up to 
230 µg/L Ag in blood (normal Ag concentrations are less than 1µg /L) has been reported with up to 28-
day applications of NAg-containing dressings on burns58. Importantly, Trop et al. detected a 140-fold 
silver level increase in urine at the end of a 7-day treatment course with NAg dressings on burns (relative 
to the normal concentration of 0.2 µg Ag/kg)59, and as also reported in other studies, persisted before 
gradually returning to normal levels following discontinuation of the NAg treatment59,60. Silver in urine 
and therefore in urinary tract, is thought to result from Ag ions and small-sized organo Ag species in the 
bloodstream passing through the kidney filtration system61. Such prolonged presence of bioavailable 
silver raises the possibility of development of resistant microorganisms (also see Table S3 for forms of 
silver species in urine and their bioavailability). Similar to wounds, the urinary tract is a microbial habitat. 
Apart from the known prevalence of fast-growing microorganisms, quite recent innovations in 
biomolecular techniques have allowed identification of slow-growing and delicate microorganisms 
dwelling in the urinary tract, which are otherwise uncultivable with traditional methods62. The potential 
for exposure of these unique microbial communities to bioavailable silver is even more likely with the use 
of NAg (or Ag)-containing urinary catheters with on-site prolonged release of Ag ions. 
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Similarly concerning are the widely marketed NAg dietary supplements. More than simply marketing 
hype, studies have validated the claimed presence of NAg particulates in many oral supplements as well 
as in throat and nasal sprays63-65. These NAg (or Ag) applications are likely to facilitate direct 
accumulation of bioavailable silver in organs and tissues with resident commensal microflora. Without 
the need for systemic absorption into the bloodstream, deposition of bioavailable silver in the oral cavity 
and gastrointestinal tract is anticipated following oral intake and ingestion of silver51,66 or in the 
respiratory tract following inhalation of silver65,67. These densely-populated microbial habitats harbour 
widely diverse microbial communities – including Bacillus sp. as members1,68-71, that are potentially 
responsive to the prolonged presence of bioavailable silver to develop resistance effects (see Table S2 and 
S3 for more details on the fates, chemical transformation and the potential of prolonged microorganism 
exposure to bioavailable silver at these sites). Not surprisingly, there have been reports of members of gut 
microflora carrying functional sil genes, with proven resistance to silver35,48. Furthermore, systemic 
absorption of silver through the buccal (oral cavity)51, gastrointestinal30,51 and lung alveolar51 mucosa has 
been associated with detection of elevated and persistent silver levels in urine72-74 and therefore 
ultimately, the potential for prolonged exposure of urinary microflora to bioavailable silver. The 
resistance potential aside, the intended accumulation of bioavailable silver in the gut with Ag ingestion 
could eradicate beneficial resident microflora, leading to colonisation and overgrowth of pathogens in the 
gut75. It has also been well established that changes in the dynamic and balance of gut microflora may 
lead to an array of undesirable host functions, including inflammation and disrupted energy balance1,76.  
Development of resistance to bioavailable silver by microorganisms residing in an individual increases 
the vulnerability of that individual to infections arising, for example, from medical procedures relying on 
silver as an antimicrobial in situations whereby antibiotics are less effective (e.g. insertion of catheter). 
The resistant microorganisms may spread to other individuals and to the environment and simply 
increases the pool of resistance determinants. Silver resistance determinants have been increasingly 
detected in a wide range of clinical and environmental microorganisms isolated from ‘ordinary’ spots 
such as hospitals and industrial sites6 to ‘exclusive’ locations including the water management systems of 
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the International Space Station77. With and without known exposure to silver, these microbes carry sil 
genes or sil gene-related silver resistance systems, many of which are highly conserved and are located in 
plasmids as transferrable genetic elements6. Such resistance determinants can be passed on to other 
microorganisms by horizontal gene transfer6,78, which appears, at least in part, to have facilitated the 
spread of resistance. Given the numerous human body microbial habitats as the resistance-prone sites, the 
prospect for microorganism-to-microorganism spread of resistance is high with the applications of NAg. 
In general, the rate of gene transfer among members of human microflora is 25-fold higher than those in 
other environments79, potentially giving rise to new resistant populations beyond the original sites, even 
with an already fading presence of bioavailable silver. 
Conclusions and Outlook 
To conclude, the need for targeted surveillance for the development of microbial resistance in NAg 
commercialisation has been invoked by: (i) the discovery that microorganisms can adapt to the cytotoxic 
bioavailable silver and becoming resistant to it, (ii) the widespread use of NAg creating opportunities for 
prolonged exposure of microbial communities to bioavailable silver, and (iii) the potential for spread of 
resistance determinants, even to other microorganisms without prior exposure to bioavailable silver. 
Whereby NAg applications are considered effective, such as those in wound dressings and catheters, 
regular monitoring for resistance development in microbial communities is recommended – on contact 
sites as well as in other human body microbial habitats with persistent presence of systemically absorbed 
bioavailable silver. The prospect for resistance development is even more intimidating considering the 
fact that ‘real world’ applications of NAg mostly deal with the more resilient microbial communities 
known as biofilms, including those found colonising wounds and surfaces of catheters80-84. The different 
microbial species in biofilms with their different genotypic and phenotypic traits unite synergistically as a 
heterogenous and dynamic entity, rendering them less susceptible to antimicrobial agents, including 
silver85. When subjected to ionic or nanocrystalline silver-containing wound treatments, studies have 
observed less susceptibility of clinically-relevant bacterial biofilms in comparison to their planktonic 
counterparts86,87. Further, these investigations were focused on single species biofilms and therefore may 
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not reflect the ‘true’ toughness of polymicrobial biofilms found in most cases of medical diseases and in 
nature85. 
In addition to targeted surveillance for resistance development, the widespread use of NAg needs to be 
cautiously reassessed for a variety of applications with respect to their risks versus benefits10,88. For 
example, along with the herein realised potential for resistance development, the NAg dietary 
supplements are marketed based on unverified claims of “immune system boost” and with no clearly 
defined antimicrobial targets. Also worth highlighting are the complex and yet seemingly inadequate 
regulations currently placed upon NAg, creating numerous commercialisation loopholes for NAg use. 
The labelling of NAg supplements as “dietary supplements” for instance, have rendered them essentially 
immune to the US Food and Drug Administration (FDA)’s strict premarket New Drug Application 
(NDA) authorisation until after they are already on the market88. Similar to that under the European 
Union’s REACH legislation (Registration, Evaluation, Authorization and Restriction of Chemicals)89 and 
Australia’s NICNAS (National Industrial Chemicals and Assessment Scheme)90, NAg does not meet the 
criteria as ‘new chemical’ under the US Environmental Protection Agency (EPA)’s Toxic Substances 
Control Act (TSCA) with the compositionally identical bulk form silver already on the Chemical 
Substance Inventory91. Such classification has let companies to subject NAg to the same toxicity testing 
and reporting requirements as bulk silver91. This is despite the significant scholarly research reporting 
differences in their physical and chemical characteristics and consequently, their risks on human and 
environmental health, as also highlighted in numerous reports by the European Commission’s 
SCENIHR9,91,92. The US EPA now acknowledges these differences and assesses NAg separately to bulk 
silver. As a start, pesticide products that contain NAg must now be registered prior to their release, with 
the EPA already issuing ‘conditional approval’ for two products since 201110. Numerous NAg products, 
however, had been launched prior to this change in EPA rules and these products remain in the market, 
still promoted based on toxicity evaluation for regular silver10.  
With this Perspective, we seek to raise awareness of the genuine potential for the current widespread 
use of NAg to lead to development of microbial resistance and we argue the need for a judicial approach 
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towards NAg usage. Without effective regulated use of NAg and without efforts to monitor for potential 
(or realised) resistance development, the capacity of NAg as an alternative antimicrobial weapon in the 
era of increasing antibiotic resistance will be diminished. The hazard presented by indiscriminate use of 
NAg is further underscored by intriguing new evidence of shifts in antibiotic resistance gene profiles in 
microbial communities when subjected to presence of NAg93. Beyond a weakened antimicrobial arsenal, 
unnecessary applications of NAg will unnecessarily change the balance and dynamics of endogenous 
microflora, not only those that dwell in the human body but also in the environment. The ripple effect of 
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54. Ballatori, N. Glutathione Mercaptides as Transport Forms of Metals. Adv. Pharmacol. 1994, 27, 271-
298. 
55. Shoeib, T.; Siu, K. W. M.; Hopkinson, A. C. Silver Ion Binding Energies of Amino Acids: Use of 
Theory to Assess the Validity of Experimental Silver Ion Basicities Obtained from the Kinetic 
Method. J. Phys. Chem. A 2002, 106, 6121-6128. 
56. Jover, J.; Bosque, R.; Sales, J. Quantitative Structure-Property Relationship Estimation of Cation 
Binding Affinity of the Common Amino Acids. J. Phys. Chem. A 2009, 113, 3703-3708. 
57. Lee, V. W. –M.; Li, H.; Lau, T. –C.; Guevremont, R.; Siu, K. W. M. Relative Silver(I) Ion Binding 
Energies of -Amino Acids: A Determination by Means of the Kinetic Method. J. Am. Soc. Mass 
Spectrom. 1998, 9, 760-766. 
58. Vlachou, E.; Chipp, E.; Shale, E.; Wilson, Y. T.; Papini, R.; Moiemen, N. S. The Safety of 
Nanocrystalline Silver Dressings on Burns: A Study of Systemic Silver Absorption. Burns 2007, 33, 
979-985. 
59. Trop, M.; Novak, M.; Rodl, S.; Hellbom, B.; Kroell, W.; Goessler, W. Silver-Coated Dressing 
Acticoat Caused Raised Liver Enzymes and Argyria-Like Symptoms in Burn Patient. J. Trauma-Injury 
Infect. Crit. Care 2006, 60, 648-652. 
60. Chen, J.; Han, C. M.; Yu, C. H. The Change of the Metabolism of Silver in Silver Nanoparticle 
Dressing on Burn Wounds. Chin. J. Burns 2004, 20, 161-163. 
61. Burk, R. F.; Hill, K. E. Selenoprotein P – Expression, Functions, and Roles in Mammals. Biochim. 
Biophys. Acta 2009, 1790, 1441-1447. 
62. Whiteside, S. A.; Razvi, H.; Dave, S.; Reid, G.; Burton, J. P. The Microbiome of the Urinary Tract – A 
Role beyond Infection. Nat. Rev. Urol. 2015, 12, 81-90. 
Perspective 
 
    18 
 
63. Sánchez-Pomales, G.; Mudalige, T. K.; Lim, J. –H.; Linder, S. W. Rapid Determination of Silver in 
Nanobased Liquid Dietary Supplements Using a Portable X-Ray Fluorescence Analyzer. J. Agric. 
Food Chem. 2013, 61, 7250-7257. 
64. Reed, R. B.; Faust, J. J.; Yang, Y.; Doudrick, K.; Capco, D. G.; Hristovski, K.; Westerhoff, P. 
Characterization of Nanomaterials in Metal Colloid-Containing Dietary Supplement Drinks and 
Assessment of Their Potential Interactions after Ingestion. ACS Sustainable Chem. Eng. 2014, 2, 1616-
1624. 
65. Quadros, M. E.; Marr, L. C. Silver Nanoparticles and Total Aerosols Emitted by Nanotechnology-
Related Consumer Spray Products. Environ. Sci. Technol. 2011, 45, 10713-10719. 
66. Bouwmeester, H. et al. 2007; 
http://www.researchgate.net/profile/Hans_Bouwmeester/publication/40103450_Health_impact_of_nan
otechnologies_in_food_production.pdf (2007). 
67. Hinds, W. C. Aerosol Technology, p. 483 (Wiley-Interscience, New York, 1999). 
68. Dewhirst, F. E.; Chen, T.; Izard, J.; Paster, B. J.; Tanner, A. C. R.; Yu, W. –H.; Lakshmanan, 
A.; Wade, W. G. The Human Oral Microbiome. J. Bacteriol. 2010, 192, 5002-5017. 
69. Hilty, M.; Burke, C.; Pedro, H.; Cardenas, P.; Bush, A.; Bossley, C.; Davies, J.; Ervine, A.; Poulter, L.; 
Pachter, L.; Moffatt, M. F.; Cookson, W. O. C.  Disordered Microbial Communities in Asthmatic 
Airways. PLoS One 2010, 5, e8578. 
70. Willing, B. P.; Antunes, L. C. M.; Keeney, K. M.; Ferreira, R. B. R.; Finlay, B. B. Harvesting the 
Biological Potential of the Human Gut Microbiome. BioEssays 2011, 33, 414-418. 
71. Bottone, E. J. Bacillus cereus, a Volatile Human Pathogen. Clin. Microbiol. Rev. 2010, 23, 382-398. 
72. Blumberg, H.; Carey, T. N. Argyremia: Detection of Unsuspected and Obscure Argyria by the 
Spectrographic Demonstration of High Blood Silver. J. Am. Med. Assoc. 1934, 103, 1521-1524. 
73. White, J. M. L.; Powell, A. M.; Brady, K.; Russell-Jones, R. Severe Generalized Argyria Secondary to 
Ingestion of Colloidal Silver Protein. Clin. Experim. Dermatol. 2003, 28, 254-256. 
74. Rosenman, K. D.; Seixas, N.; Jacobs, I. Potential Nephrotoxic Effects of Exposure to Silver. Br. J. Ind. 
Med. 1987, 44, 267-272. 
Perspective 
 
    19 
 
75. Hooker, K. D.; DiPiro, J. T. Effect of Antimicrobial Therapy on Bowel Flora. Clin. Pharm. 1988, 7, 
878-888. 
76. Febinia, C.; Ha, C.; Le, C.; Holmes, A. The Role of the Gut Microbiome in Host Systems. Microbiol. 
Aust. 2015, 36, 14-17. 
77. Mijnendonckx, K.; Provoost, A.; Ott, C. M.; Venkateswaran, K.; Mahillon, J.; Leys, N.; Van Houdt, R. 
Characterization of the survival ability of Cupriavidus metallidurans and Ralstonia pickettii from 
space-related environments. Microb. Ecol. 2013, 65, 347-360. 
78. Ochman, H.; Lawrence, J. G.; Groisman, E. A. Lateral Gene Transfer and the Nature of Bacterial 
Innovation. Nature 2000, 405, 299-304. 
79. Smillie, C. S.; Smith, M. B.; Friedman, J.; Cordero, O. X.; David, L. A.; Alm, E. J. Ecology Drives a 
Global Network of Gene Exchange Connecting to the Human Microbiome. Nature 2011, 480, 241-244. 
80. Lindsay, D.; von Holy, A. Bacterial Biofilms within the Clinical Setting: What Healthcare 
Professionals Should Know. J. Hosp. Infect. 2006, 64, 313-325. 
81. James, G. A.; Swogger, E.; Wolcott, R.; Pulcini, E. D.; Secor, P.; Sestrich, J.; Costerton, J. 
W.; Stewart, P. S. Biofilms in Chronic Wounds. Wound Repair Regen. 2008, 16, 37-44. 
82. Inglis, T. J.; Millar, M. R.; Jones, J. G.; Robinson, D. A. Tracheal Tube Biofilm as a Source of Bacterial 
Colonization of the Lung. J. Clin. Microbiol. 1989, 27, 2014-2018. 
83. Nickel, J. C.; Downey, J. A.; Costerton, J. W. Ultrastructural Study of Microbiologic Colonization of 
Urinary Catheters. Urology 1989, 34, 284-291. 
84. Percival, S. L.; Knapp, J. S.; Edyvean, R. G. J.; Wales, D. S. Biofilm Development on Stainless Steel in 
Mains Water. Water Res. 1998, 32, 243-253. 
85. Rhoads, D. D.; Wolcott, R. D.; Percival, S. L. Biofilms in Wounds: Management Strategies. J. Wound 
Care 2008, 17, 502-508. 
86. Percival, S. L.; Bowler, P.; Dolman, J. Antimicrobial Activity of Silver-Containing Dressings on Wound 
Microorganisms Using an In Vitro Biofilm Model. Int. Wound J. 2007, 4, 186-191. 
87. Bjarnsholt, T.; Kirketerp-Møller, K.; Kristiansen, S.; Phipps, R.; Nielsen, A. K.; Jensen, P. Ø.; Høiby, 
N.; Givskov, M. Silver against Pseudomonas aeruginosa Biofilms. APMIS 2007, 115, 921-928.  
Perspective 
 
    20 
 
88. Lipman, A. G. Dietary Supplements: A Call to Action. J. Pain Palliat. Care Pharmacother. 2010, 24, 
330-332. 
89. REACH 2007; http://ec.europa.eu/environment/chemicals/nanotech/pdf/report_ripon1.pdf  
90. NICNAS 2013; https://www.nicnas.gov.au/communications/issues/nanomaterials-
nanotechnology/nicnas-technical-activities-in-nanomaterials/nano-silver-health-hazard-review/silver-
nanomaterial-factsheet  
91. Faunce, T.; Watal, A. Nanosilver and Global Public Health: International Regulatory Issues. 
Nanomedicine 2010, 5, 617-632. 
92. Hansen, S. F.; Baun, A. When Enough is Enough. Nat. Nanotechnol. 2012, 7, 409-411. 
93. Ma, Y.; Metch, J. W.; Yang, Y.; Pruden, A.; Zhang, T. Shift in Antibiotic Resistance Gene Profiles 






































    22 
 
   
Figure 2. Resistance-prone sites: potential prolonged exposure of resident commensal microflora to the 
presence of bioavailable silver in various human body locations. Presence of bioavailable silver is through 
release, absorption, distribution and accumulation of silver species from nanosilver products. 
 
 
 
 
 
 
 
